State Street’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,602
| Closed | -$4.29K | – | 4591 |
|
|
2023
Q3 | $4.29K | Hold |
11,602
| – | – | ﹤0.01% | 4542 |
|
|
2023
Q2 | $13.6K | Hold |
11,602
| – | – | ﹤0.01% | 4629 |
|
|
2023
Q1 | $19.7K | Sell |
11,602
-7,200
| -38% | -$18.3K | ﹤0.01% | 4683 |
|
|
2022
Q4 | $59.8K | Buy |
+18,802
| New | +$113K | ﹤0.01% | 4516 |
|
|
2022
Q1 | – | Sell |
-203
| Closed | -$62K | – | 4961 |
|
|
2021
Q4 | $62K | Hold |
203
| – | – | ﹤0.01% | 4669 |
|
|
2021
Q3 | $160K | Hold |
203
| – | – | ﹤0.01% | 4427 |
|
|
2021
Q2 | $216K | Buy |
+203
| New | +$266K | ﹤0.01% | 4194 |
|
|
2020
Q3 | – | Sell |
-18
| Closed | -$102K | – | 3878 |
|
|
2020
Q2 | $102K | Sell |
18
-103
| -85% | -$494K | ﹤0.01% | 3657 |
|
|
2020
Q1 | $421K | Buy |
121
+5
| +4% | +$47.2K | ﹤0.01% | 3479 |
|
|
2019
Q4 | $1.13M | Buy |
+116
| New | +$990K | ﹤0.01% | 3384 |
|
State Street's BXRX Position: Q4 2023 in Review
State Street sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 11,602 shares — an estimated $4.29K sold.
State Street first reported a position in BXRX in Q4 2019 and held it in 10 quarters. The position peaked at $1.13M in Q4 2019. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.
- State Street reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- State Street sold 11,602 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $4.29K.
- State Street first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
- State Street's Baudax Bio, Inc. Common Stock position peaked at $1.13M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.
Based on State Street's 13F filing for Q4 2023, filed 14 Feb 2024.